Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world first-line maintenance study of senaparib in newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer
ChiCTR2600132467Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Incidence of side effects. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
senaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600132467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132467.